Envestnet Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Envestnet Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-89,207	Closed	-$252K	–	3229
2020 Q1	$252K	Sell	89,207 -2,716	-3%	-$8.76K	﹤0.01%	2633
2019 Q4	$298K	Buy	91,923 +15,207	+20%	+$44.1K	﹤0.01%	2732
2019 Q3	$166K	Buy	76,716 +5,152	+7%	+$13.8K	﹤0.01%	2906
2019 Q2	$225K	Buy	71,564 +585	+0.8%	+$1.9K	﹤0.01%	2828
2019 Q1	$264K	Buy	+70,979	New	+$240K	﹤0.01%	2671
2018 Q3	–	Sell	-704	Closed	-$1K	–	3149
2018 Q2	$1K	Hold	704	–	–	﹤0.01%	2851
2018 Q1	$2K	Buy	704 +500	+245%	+$1.36K	﹤0.01%	2752
2017 Q4	$1K	Sell	204 -14,079	-99%	-$43.2K	﹤0.01%	2953
2017 Q3	$49K	Buy	14,283 +13,579	+1,929%	+$37.8K	﹤0.01%	2290
2017 Q2	$2K	Buy	704 +500	+245%	+$1.15K	﹤0.01%	2977
2017 Q1	$0	Sell	204 -5,413	-96%	-$12K	﹤0.01%	3253
2016 Q4	$11K	Sell	5,617 -1,095	-16%	-$3.06K	﹤0.01%	2766
2016 Q3	$22K	Sell	6,712 -376	-5%	-$1.19K	﹤0.01%	2804
2016 Q2	$22K	Sell	7,088 -7,096	-50%	-$23.7K	﹤0.01%	2957
2016 Q1	$47K	Sell	14,184 -581	-4%	-$1.81K	﹤0.01%	2747
2015 Q4	$52K	Buy	14,765 +3,079	+26%	+$12.9K	﹤0.01%	2665
2015 Q3	$59K	Buy	+11,686	New	+$67K	﹤0.01%	2574
2015 Q1	–	Sell	-450	Closed	-$3K	–	2682
2014 Q4	$3K	Hold	450	–	–	﹤0.01%	2300
2014 Q3	$3K	Sell	450 -946	-68%	-$8.78K	﹤0.01%	2467
2014 Q2	$14K	Buy	+1,396	New	+$12.4K	﹤0.01%	1906
2014 Q1	–	Sell	-316	Closed	-$3K	–	2746
2013 Q4	$3K	Hold	316	–	–	﹤0.01%	2204
2013 Q3	$3K	Sell	316 -567	-64%	-$4.56K	﹤0.01%	2123
2013 Q2	$7K	Buy	+883	New	+$6.88K	﹤0.01%	1814

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Envestnet Asset Management's PDLI Position: Q2 2020 in Review

Envestnet Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2020, closing a stake of 89,207 shares — an estimated $252K sold.

Envestnet Asset Management first reported a position in PDLI in Q2 2013 and held it in 23 quarters. The position peaked at $298K in Q4 2019. 136 funds tracked by Wall St. Rank hold PDLI as of Q2 2020.

Envestnet Asset Management reported no remaining PDL BioPharma, Inc. position as of Q2 2020 after selling out during the quarter.
Envestnet Asset Management sold 89,207 PDL BioPharma, Inc. shares in Q2 2020, an estimated $252K.
Envestnet Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 23 quarters.
Envestnet Asset Management's PDL BioPharma, Inc. position peaked at $298K in Q4 2019.
136 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2020.

Based on Envestnet Asset Management's 13F filing for Q2 2020, filed 8 Jul 2020.